Plasma metabolites distinguish dementia with Lewy bodies from Alzheimer’s disease: a cross-sectional metabolomic analysis

Plasma metabolites distinguish dementia with Lewy bodies from Alzheimer’s disease: a cross-sectional metabolomic analysis

BackgroundIn multifactorial diseases, alterations in the concentration of metabolites can identify novel pathological mechanisms at the intersection between genetic and environmental influences. This study aimed to profile the plasma metabolome of patients with dementia with Lewy bodies (DLB) and Al...

Full description

Bibliographic Details
Main Authors:	Xiaobei Pan, Paul C. Donaghy, Gemma Roberts, Leonidas Chouliaras, John T. O’Brien, Alan J. Thomas, Amanda J. Heslegrave, Henrik Zetterberg, Bernadette McGuinness, Anthony P. Passmore, Brian D. Green, Joseph P. M. Kane
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Aging Neuroscience
Subjects:	dementia Lewy body dementia Alzheimer’s disease metabolomic analyses biomarkers
Online Access:	https://www.frontiersin.org/articles/10.3389/fnagi.2023.1326780/full

Similar Items

Commentary: Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
by: Thomas K. Karikari, et al.
Published: (2018-03-01)

Alzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint
by: Deborah O. T. Alawode, et al.
Published: (2022-04-01)

The Cerebrospinal Fluid in Multiple Sclerosis
by: Florian Deisenhammer, et al.
Published: (2019-04-01)

Neuromodulation via the Cerebrospinal Fluid: Insights from Recent in Vitro Studies
by: Andreas Bjorefeldt, et al.
Published: (2018-02-01)

High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis
by: Igal Rosenstein, et al.
Published: (2023-01-01)

Association between APOE genotype and change in physical function in a population-based Swedish cohort of older individuals followed over four years.
by: Ingmar Skoog, et al.
Published: (2016-10-01)

Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population
by: Helena Sophia Gleerup, et al.
Published: (2021-05-01)

Fluid biomarkers and risk of neurodegenerative disease in retired athletes with multiple concussions: results from the International Concussion and Head Injury Research Foundation Brain health in Retired athletes Study of Ageing and Impact-Related Neurodegenerative Disease (ICHIRF-BRAIN study)
by: Michael Turner, et al.
Published: (2022-09-01)

Stability of blood‐based biomarkers of Alzheimer's disease over multiple freeze‐thaw cycles
by: Ashvini Keshavan, et al.
Published: (2018-01-01)

Perioperative brain injury marker concentrations in neonatal open-heart surgery: a prospective observational study
by: Åsa Jungner, et al.
Published: (2023-08-01)

Plasma Markers of Neurodegeneration Are Raised in Friedreich’s Ataxia
by: Anna M. Zeitlberger, et al.
Published: (2018-10-01)

Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis
by: Igal Rosenstein, et al.
Published: (2022-08-01)

Neurofilament light in blood – What more is needed for clinical implementation in multiple sclerosis?
by: Henrik Zetterberg
Published: (2020-07-01)

Methylenetetrahydrofolate reductase and transcobalamin genetic polymorphisms in human spontaneous abortion: biological and clinical implications
by: Zetterberg Henrik
Published: (2004-02-01)

Changes in Adiposity and Cerebrospinal Fluid Biomarkers Following a Modified Mediterranean Ketogenic Diet in Older Adults at Risk for Alzheimer’s Disease
by: Tina E. Brinkley, et al.
Published: (2022-06-01)

A Strategy for Discovery and Verification of Candidate Biomarkers in Cerebrospinal Fluid of Preclinical Alzheimer’s Disease
by: Xiaofang Zhong, et al.
Published: (2019-01-01)

Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome
by: Andre Strydom, et al.
Published: (2018-04-01)

Elucidating distinct molecular signatures of Lewy body dementias
by: Joshua Harvey, et al.
Published: (2023-11-01)

Plasma neurofilament light chain protein is not increased in forensic psychiatric populations: a pilot study
by: Anja Fernqvist, et al.
Published: (2023-05-01)

Editorial: Blood Biomarkers of Neurodegenerative Diseases
by: Thomas K. Karikari, et al.
Published: (2022-06-01)

The Shape of Things to Come. An Interview with Henrik Zetterberg-Nielsen
by: Henrik Zetterberg-Nielsen
Published: (2022-07-01)

Bioinformatics tools and data resources for assay development of fluid protein biomarkers
by: Katharina Waury, et al.
Published: (2022-11-01)

A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis
by: Sofia Sandgren, et al.
Published: (2023-09-01)

Shared CSF Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus and Subcortical Small Vessel Disease
by: Anna Jeppsson, et al.
Published: (2022-03-01)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
by: Henrik Zetterberg, et al.
Published: (2021-02-01)

High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis
by: Avadhesh Kumar Singh, et al.
Published: (2017-03-01)

Examining four blood biomarkers for the detection of acute intracranial abnormalities following mild traumatic brain injury in older adults
by: Grant L. Iverson, et al.
Published: (2022-11-01)

Differential chemokine alteration in the variants of primary progressive aphasia—a role for neuroinflammation
by: Aitana Sogorb-Esteve, et al.
Published: (2021-10-01)

Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
by: Lars Lau Raket, et al.
Published: (2020-01-01)

Sex difference in circulating soluble form of ACE2 protein in moderate and severe COVID-19 and healthy controls
by: Josefina Robertson, et al.
Published: (2022-12-01)

Blood-based molecular biomarkers for Alzheimer’s disease
by: Henrik Zetterberg, et al.
Published: (2019-03-01)

Neurodegenerative dementias: screening for major threats to healthy longevity with blood biomarkers
by: Henrik Zetterberg, et al.
Published: (2021-02-01)

Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group
by: Fabrizia D'Antonio, et al.
Published: (2021-01-01)

Lewy Body Dementias: A Coin with Two Sides?
by: Ángela Milán-Tomás, et al.
Published: (2021-06-01)

Inflammation in dementia with Lewy bodies
by: Jay Amin, et al.
Published: (2022-06-01)

Dementia with lewy bodies - diagnosis and treatment
by: IG McKeith
Published: (2003-03-01)

Lewy Body Dementia Association’s Research Centers of Excellence Program: Inaugural Meeting Proceedings
by: Bethany Peterson, et al.
Published: (2019-03-01)

Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
by: Fernando Gonzalez-Ortiz, et al.
Published: (2023-03-01)

Neurological involvement among non-hospitalized adolescents and young adults 6 months after acute COVID-19
by: Lise Beier Havdal, et al.
Published: (2024-02-01)

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
by: Kristi Henjum, et al.
Published: (2018-11-01)